Document 1114
 DOCN  M94A1114
 TI    Is zidovudine effective in asymptomatic Chinese HIV carriers?
 DT    9412
 AU    Twu SJ; Lin HC; Chuang CY; National Taiwan University, Venereal Disease
       Control Center,; Taipei, R.O.C.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):206 (abstract no. PB0837). Unique
       Identifier : AIDSLINE ICA10/94371461
 AB    Human immunodeficiency viral (HIV) infection has spread to almost every
       country in the world and Asia will be the most prevalent area in year
       2000. Zidovudine (AZT) has been documented to be effective in the
       treatment of acquired immunodeficiency syndrome (AIDS) and in the
       prophylactic therapy of asymptomatic HIV infection in western countries.
       However, the effectiveness of AZT to delay the development of AIDS in
       Chinese HIV carriers has not been reported in. We have recruited 282 HIV
       infected Chinese people in Taiwan since March 1988 to September 1993.
       Most of these patients were male, asymptomatic, aged 25-34. AZT was
       given to 133 patients after written informed consent. These patients
       were followed up regularly every 3 months with the measurement of
       complete blood cell count, number of CD4 and CD8 T cell and physical
       examination. The number of CD4 T cell increased as early as 3 months
       after AZT treatment compared to that at the recruitment and lasted up to
       15 months after treatment. After 18 months of treatment, no more
       increase of the numbering CD4 T cell was seen. The number of CD8 T cell
       decreased for only 6 months after treatment compared to that at
       recruitment and increased again thereafter. Side effects included the
       decrease of white blood cell and hemoglobin, nausea, anorexia, insomnia,
       headache. Compared to the results, reported in western countries, our
       study showed that AZT is as effective in the prophylactic treatment for
       Chinese people with HIV infection.
 DE    Adult  China  Human  HIV Infections/*DRUG THERAPY/IMMUNOLOGY  Leukocyte
       Count  Male  T4 Lymphocytes  Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).